ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital
ORIC-944 shows promising efficacy in mCRPC, with 47% PSA50 response rate. The drug is well tolerated, with most adverse events being Grade 1 or 2. A $125 million private placement will extend cash runway into 2027. Phase 3 trial expected to start in 1H 2026, following ongoing dose exploration. Current stock surge is 24.7% in premarket, indicating positive market response.
View signal analysis